Xencor Stock Price, News & Analysis

Xencor (NASDAQ:XNCR) reported Q2 2025 financial results and clinical program updates. The company recorded revenue of $43.6 million, up from $23.9 million in Q2 2024, and a net loss of $30.8 million. Cash position stands at $663.8 million, expected to fund operations into 2028.

Key clinical developments include progress in four wholly owned XmAb® programs: XmAb819 and XmAb541 for cancer treatment, with initial XmAb819 data expected in Q4 2025; the Phase 2b XENITH-UC study of XmAb942 for ulcerative colitis; and plamotamab for rheumatoid arthritis. Additionally, Xencor received a $25 million milestone payment from Incyte following FDA approval of Monjuvi for follicular lymphoma.

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, has appointed Dr. Raymond J. Deshaies to its board of directors. Dr. Deshaies brings over 25 years of biotechnology and drug development experience, most recently serving as senior vice president of global research at Amgen.

During his tenure at Amgen, Dr. Deshaies oversaw the nomination of over 50 clinical candidates and expanded capabilities in multispecific drug discovery. His notable achievements include co-founding Proteolix, which developed KYPROLIS® for multiple myeloma treatment, and founding Cleave Biosciences. He is a distinguished member of both the American Academy of Arts and Sciences and the National Academy of Sciences.

Xencor (NASDAQ:XNCR) reported its Q1 2025 financial results and business updates. The company's XmAb942 Phase 1 study showed promising results, supporting a 12-week maintenance dosing interval for ulcerative colitis treatment, with Phase 2b XENITH-UC study planned for H2 2025. Chief Development Officer Nancy Valente will transition to a senior advisory role in June 2025. Financially, Xencor reported Q1 2025 revenue of $32.7M (up from $16.0M in Q1 2024), with a net loss of $48.4M ($0.66 per share). The company maintains a strong cash position of $693.5M as of March 31, 2025, expecting to fund operations into 2028. Notable partnership developments include milestone payments from Incyte ($12.5M) and Vir Biotechnology ($2.0M).

Xencor announced positive interim results from its first-in-human study of XmAb942, a high-potency antibody treatment for inflammatory bowel disease. The study showed promising safety and efficacy data, with key findings including:

• Well-tolerated safety profile at single and multiple doses
• Extended half-life of over 71 days, supporting 12-week maintenance dosing
• No serious adverse events reported
• No evidence of anti-drug antibodies

The company plans to advance to XENITH-UC, a Phase 2b study in ulcerative colitis patients, starting in second half of 2025. This randomized trial will enroll approximately 220 patients across three dose levels. Additionally, Xencor's TL1A x IL23p19 bispecific antibody program is progressing toward human trials in 2026.

Xencor (NASDAQ:XNCR) announced the appointment of Todd Simpson to its board of directors. Simpson brings over 40 years of experience in CFO roles and public accounting, most notably serving as CFO at Seagen Inc. until its 2023 acquisition.

During his 18-year tenure at Seagen, Simpson was instrumental in the development and commercialization of four oncology medicines across multiple indications in the US. He led the company's international expansion, resulting in the commercialization of three medicines in the Americas and Europe. His responsibilities included oversight of global finance, strategic planning, tax, treasury, corporate real estate, facilities, investor relations, corporate communications, and IT.

Simpson currently serves on the board of Shape Therapeutics and previously held board positions at Neoleukin Therapeutics, Aquinox Pharmaceuticals, and Life Science Washington. He is a certified public accountant and holds a B.S. in accounting and computer science from Oregon State University.

Xencor (NASDAQ:XNCR) reported its Q4 and full year 2024 financial results, highlighting strategic pipeline rebalancing focused on XmAb® drug candidates. The company ended 2024 with $706.7 million in cash and equivalents, projecting sufficient funding into 2028.

Q4 2024 revenue was $52.8 million, with full-year revenue at $110.5 million. The company reported a Q4 net loss of $45.6 million ($0.62 per share) and a full-year net loss of $232.6 million ($3.58 per share).

Key clinical updates include progress on XmAb942 for inflammatory bowel disease, XmAb819 for renal cell carcinoma, and XmAb541 for solid tumors. The company earned a $30 million milestone payment from Amgen and $4 million from Novartis in Q4 2024.

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for cancer and serious diseases treatment, has announced its participation in two major investor conferences. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York City on December 3, 2024, at 2:00 p.m. ET, and at the 7th Annual Evercore HealthCONx Conference in Coral Gables, Florida on December 4, 2024, at 3:50 p.m. ET. Live webcasts will be available on Xencor's website under the Investors section, with replays accessible for at least 30 days after the presentations.

Xencor (NASDAQ:XNCR) reported Q3 2024 financial results with revenues of $10.7 million, down from $59.2 million in Q3 2023. The company posted a net loss of $45.1 million, or $(0.71) per share. Cash position stood at $754.3 million after raising $201.3 million through a public offering. R&D expenses decreased to $58.2 million from $64.9 million year-over-year. The company highlighted progress in its clinical pipeline, including XmAb942 entering Phase 1 trials and partner Amgen advancing xaluritamig to Phase 3 for prostate cancer. Xencor expects to end 2024 with $690-710 million in cash, funding operations into 2028.

Xencor (NASDAQ: XNCR) has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, a high-potency extended half-life anti-TL1A antibody for inflammatory bowel disease. The Phase 1/2 randomized, double-blind, placebo-controlled study will be conducted in three parts: Phase 1 Part A for single-ascending dose cohorts, Part B for repeat doses in healthy volunteers, and Phase 2 Part C for ulcerative colitis patients. Initial data is expected in the first half of 2025. The company believes XmAb942's properties may offer improved clinical benefits and more convenient dosing compared to other anti-TL1A antibodies in development.